Evidence map›Paper›PMID 41692349›Full record

ArticleBiochemical pharmacology2026

Loss of cystathionine-β-synthase contributes to elevated OXPHOS, a vulnerability in Ara-C-resistant Myeloid Leukemia in Down syndrome.

Jenna Thibodeau, Jianlei Zhao, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H Dzinic, Kathryn White, Kian Hershberger, Yongwei Su, Tasnim Arroum and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jenna ThibodeauCancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA.
Jianlei ZhaoDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Holly EdwardsDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Lisa PolinDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Juiwanna KushnerDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Sijana H DzinicDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Kathryn WhiteDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Kian HershbergerCancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; MD/PhD Program, Wayne State University School of Medicine, Detroit, MI, USA.
Yongwei SuDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Tasnim ArroumCenter for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA.
Lucynda PhamCenter for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA.
Lauren PavelichCenter for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA.
Raina AwdishWayne State University School of Medicine, Detroit, MI, USA.
Jacob LaValleyWayne State University School of Medicine, Detroit, MI, USA.
Austin C BoucherDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Wei ChenDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Jing LiDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Xun BaoDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Maik HüttemannCancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA.
Jessica B BackDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Tumor Biology and Microenvironment Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Joshua E AllenChimerix (a Jazz Pharmaceuticals Company), Durham, NC, USA.
Varun V PrabhuChimerix (a Jazz Pharmaceuticals Company), Durham, NC, USA.
John D CrispinoDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jeffrey W TaubCancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI, USA; Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Department of Pediatrics, Central Michigan University College of Medicine, Mt. Pleasant, MI, USA. Electronic address: jtaub@med.wayne.edu.
Yubin GeCancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: gey@karmanos.org.

Funding

Tumor Biology and MicroenvironmentP30CA022453 · NCI · WAYNE STATE UNIVERSITY · 1985 to 2025
$19.2M
TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · WAYNE STATE UNIVERSITY · 1985 to 2025
$1.0M
The paradox of myeloid leukemia of Down syndromeR21CA270718 · NCI · WAYNE STATE UNIVERSITY · PI Yubin Ge, JEFFREY Warren TAUB · 2023 to 2023
$396k
Enhancing treatments for myeloid leukemia associated with Down syndromeR01CA290480 · WAYNE STATE UNIVERSITY · 2025 to 2025
$314k
NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA290480NCI NIH HHS R21 CA270718NCI NIH HHS T32 CA009531
6 · The paper itself

Abstract

Myeloid leukemia associated with Down syndrome (ML-DS), as classified by WHO 2016, includes acute myeloid leukemia (AML) and myelodysplasia in children with DS. While ML-DS patients show high sensitivity to cytarabine (Ara-C)-based chemotherapy with better overall survival than non-DS AML patients, relapsed/refractory cases have dismal outcomes. This underscores the need to understand Ara-C-resistance mechanisms and develop effective therapies. The chromosome 21 gene, cystathionine-β-synthase (CBS), is significantly overexpressed in ML-DS cells. Overexpression of CBS leads to increased hydrogen sulfide (H

Indexed as

Cystathionine beta-SynthaseCytarabineDown SyndromeDrug Resistance, NeoplasmLeukemia, MyeloidOxidative PhosphorylationAntimetabolites, AntineoplasticCell Line, TumorHumansAntimetabolites, AntineoplasticCystathionine beta-SynthaseCytarabineAra-C-resistantCBSCystathionine-β-synthaseHydrogen sulfideML-DSOXPHOS

Identifiers

PMID41692349
PMCPMC12981302

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.